CorMedix (CRMD) Financials

$12.82 +0.07 (+0.55%)

As of 05/20/2025 04:00 PM Eastern

Annual Income Statements for CorMedix

This table shows CorMedix's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-18	-46	-30
Consolidated Net Income / (Loss)	-18	-46	-30
Net Income / (Loss) Continuing Operations	-18	-46	-30
Total Pre-Tax Income	-19	-46	-30
Total Operating Income	-22	-49	-31
Total Gross Profit	40	0.00	0.06
Total Revenue	43	0.00	0.07
Operating Revenue	43	0.00	0.07
Total Cost of Revenue	3.19	0.00	0.00
Operating Cost of Revenue	3.19	0.00	0.00
Total Operating Expenses	63	49	31
Selling, General & Admin Expense	30	18	20
Marketing Expense	29	18	-
Research & Development Expense	3.94	13	11
Total Other Income / (Expense), net	3.03	2.62	0.34
Interest Expense	0.04	0.03	0.03
Interest & Investment Income	2.58	2.68	0.33
Other Income / (Expense), net	0.49	-0.03	0.04
Income Tax Expense	-1.39	0.00	-0.59
Basic Earnings per Share	($0.30)	($0.91)	($0.74)
Weighted Average Basic Shares Outstanding	58.87M	50.90M	40.27M
Diluted Earnings per Share	($0.30)	($0.91)	-
Weighted Average Diluted Shares Outstanding	58.87M	50.90M	44.50M

This table shows CorMedix's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	21	13	-2.77	-14	-14	-15	-9.75	-11	-11	-8.21	-6.85
Consolidated Net Income / (Loss)	21	13	-2.78	-14	-14	-15	-9.74	-11	-11	-8.21	-6.85
Net Income / (Loss) Continuing Operations	21	13	-2.78	-14	-14	-15	-9.74	-11	-11	-8.21	-6.85
Total Pre-Tax Income	21	13	-2.78	-14	-16	-15	-9.74	-11	-11	-8.21	-6.85
Total Operating Income	20	13	-3.29	-15	-17	-16	-10	-12	-11	-8.39	-6.96
Total Gross Profit	37	30	11	0.30	-0.82	-	0.00	0.00	0.00	0.03	0.01
Total Revenue	39	31	11	1.31	0.00	-	0.00	0.00	0.00	0.03	0.01
Operating Revenue	39	31	11	1.31	0.00	-	0.00	0.00	0.00	0.03	0.01
Total Cost of Revenue	1.60	1.18	0.69	0.51	0.82	-	0.00	0.00	0.00	0.00	0.00
Operating Cost of Revenue	1.60	1.18	0.69	0.51	0.82	-	0.00	0.00	0.00	0.00	0.00
Total Operating Expenses	17	17	14	16	16	16	10	12	11	8.42	6.97
Selling, General & Admin Expense	9.69	0.77	6.58	7.56	15	2.58	3.74	3.75	7.61	5.58	4.63
Marketing Expense	4.47	-	6.75	7.39	-	-	4.06	3.26	-	-	-
Research & Development Expense	3.19	1.73	0.73	0.65	0.84	2.29	2.66	4.79	3.41	2.84	2.34
Total Other Income / (Expense), net	0.52	1.03	0.51	0.65	0.84	0.91	0.72	0.53	0.45	0.13	0.11
Interest Expense	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01
Interest & Investment Income	0.57	0.51	0.55	0.66	0.86	0.92	0.77	0.55	0.45	0.18	0.09
Other Income / (Expense), net	-0.04	0.53	-0.03	-0.00	-0.00	0.00	-0.03	-0.01	0.01	-0.04	0.02
Income Tax Expense	0.00	-	0.00	0.00	-1.39	-	0.00	0.00	0.00	-	0.00
Basic Earnings per Share	$0.32	$0.25	($0.05)	($0.25)	($0.25)	($0.25)	($0.17)	($0.25)	($0.24)	($0.20)	($0.17)
Weighted Average Basic Shares Outstanding	65.24M	58.87M	58.83M	57.62M	57.50M	50.90M	56.55M	45.37M	44.09M	40.27M	41.18M
Diluted Earnings per Share	$0.30	-	($0.05)	-	-	-	($0.17)	-	-	-	-
Weighted Average Diluted Shares Outstanding	68.98M	58.87M	58.83M	55.86M	54.96M	50.90M	56.55M	54.81M	45.38M	44.50M	41.28M
Weighted Average Basic & Diluted Shares Outstanding	67.82M	0.00	60.68M	55.86M	54.96M	54.98M	54.81M	54.81M	45.38M	44.50M	41.28M

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	-3.07	0.45	-10
Net Cash From Operating Activities	-51	-38	-24
Net Cash From Continuing Operating Activities	-51	-38	-24
Net Income / (Loss) Continuing Operations	-18	-46	-30
Consolidated Net Income / (Loss)	-18	-46	-30
Depreciation Expense	0.15	0.07	0.08
Amortization Expense	0.30	0.13	0.12
Non-Cash Adjustments To Reconcile Net Income	6.13	5.49	4.07
Changes in Operating Assets and Liabilities, net	-39	2.23	1.07
Net Cash From Investing Activities	21	-17	-3.71
Net Cash From Continuing Investing Activities	21	-17	-3.71
Purchase of Property, Plant & Equipment	-0.12	-0.33	-0.22
Purchase of Investments	-27	-77	-31
Sale and/or Maturity of Investments	48	60	28
Net Cash From Financing Activities	26	56	18
Net Cash From Continuing Financing Activities	26	56	18
Issuance of Common Equity	19	56	18
Other Financing Activities, net	7.44	0.09	0.13
Effect of Exchange Rate Changes	-0.00	0.00	-0.01
Cash Interest Paid	0.04	0.03	0.03

This table details how cash moves in and out of CorMedix's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	26	5.36	6.75	-6.71	-8.46	-9.68	34	-5.61	-18	-0.10	-5.68
Net Cash From Operating Activities	20	-5.61	-14	-14	-17	-11	-8.70	-8.57	-10	-6.15	-6.00
Net Cash From Continuing Operating Activities	20	-5.75	-14	-14	-17	-11	-8.70	-8.57	-10	-6.15	-6.05
Net Income / (Loss) Continuing Operations	21	13	-2.78	-14	-14	-15	-9.74	-11	-11	-8.21	-6.85
Consolidated Net Income / (Loss)	21	13	-2.78	-14	-14	-15	-9.74	-11	-11	-8.21	-6.85
Depreciation Expense	0.11	0.08	0.03	0.02	0.02	0.02	0.02	0.02	0.02	0.02	0.02
Amortization Expense	0.09	0.09	0.09	0.09	0.04	0.03	0.03	0.03	0.03	0.03	0.03
Non-Cash Adjustments To Reconcile Net Income	3.50	1.19	1.23	1.26	2.44	1.22	1.00	1.06	2.22	0.87	1.35
Changes in Operating Assets and Liabilities, net	-4.62	-21	-12	-1.27	-5.35	2.74	-0.01	1.59	-2.09	1.13	-0.60
Net Cash From Investing Activities	-0.19	-0.30	6.32	6.27	8.94	0.60	-0.59	-2.39	-15	-0.00	-0.11
Net Cash From Continuing Investing Activities	-0.19	-0.30	6.32	6.27	8.94	0.60	-0.59	-2.39	-15	-0.00	-0.11
Purchase of Property, Plant & Equipment	-0.01	-0.01	-0.01	-0.03	-0.06	-0.30	-0.01	-0.01	-0.01	-0.13	-0.08
Purchase of Investments	-9.98	-5.29	-1.67	-12	-7.69	-16	-18	-17	-25	-8.77	-8.09
Sale and/or Maturity of Investments	9.80	5.00	8.00	18	17	17	18	15	11	8.90	8.05
Net Cash From Financing Activities	6.09	11	14	1.06	-0.10	0.47	43	5.35	7.20	6.05	0.44
Net Cash From Continuing Financing Activities	6.09	11	14	1.06	-0.10	0.47	43	5.35	7.20	6.05	0.44
Issuance of Common Equity	6.76	5.51	12	-	-	0.43	43	-	-	6.05	0.31
Other Financing Activities, net	-0.67	5.78	1.71	0.05	-0.10	0.03	0.02	-7.16	7.20	-	0.13
Effect of Exchange Rate Changes	0.00	-0.00	0.00	-0.00	-0.00	0.00	-0.00	0.00	0.00	0.02	-0.01
Cash Interest Paid	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01

This table presents CorMedix's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	119	82	62
Total Current Assets	115	79	60
Cash & Equivalents	41	44	43
Restricted Cash	0.00	0.08	0.12
Short-Term Investments	11	32	16
Accounts Receivable	52	0.00	-
Inventories, net	7.60	2.11	0.00
Prepaid Expenses	3.63	1.24	0.63
Plant, Property, & Equipment, net	1.83	1.87	1.61
Total Noncurrent Assets	2.44	0.74	0.88
Long-Term Investments	0.11	0.10	0.10
Intangible Assets	1.84	0.00	-
Other Noncurrent Operating Assets	0.49	0.64	0.78
Total Liabilities & Shareholders' Equity	119	82	62
Total Liabilities	34	12	6.98
Total Current Liabilities	34	11	6.31
Accounts Payable	1.72	4.28	2.20
Accrued Expenses	32	6.97	3.97
Other Current Liabilities	0.17	0.15	0.13
Total Noncurrent Liabilities	0.35	0.52	0.67
Other Noncurrent Operating Liabilities	0.35	0.52	0.67
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	85	70	55
Total Preferred & Common Equity	85	70	55
Preferred Stock	0.00	0.00	0.00
Total Common Equity	85	70	55
Common Stock	424	392	330
Retained Earnings	-340	-322	-275
Accumulated Other Comprehensive Income / (Loss)	0.09	0.09	0.08

This table presents CorMedix's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	3/31/2025	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	150	78	58	68	91	57	59	62
Total Current Assets	145	73	53	63	89	55	57	60
Cash & Equivalents	66	35	29	35	53	20	25	43
Short-Term Investments	11	11	17	23	33	33	30	16
Accounts Receivable	55	17	0.21	-	-	-	-	0.00
Inventories, net	7.49	6.65	4.01	2.32	-	-	-	0.00
Prepaid Expenses	5.26	3.09	3.37	2.46	2.39	2.14	1.05	0.55
Plant, Property, & Equipment, net	1.73	1.90	1.92	1.91	1.59	1.60	1.61	1.50
Total Noncurrent Assets	2.99	2.53	2.62	2.71	0.78	0.81	0.84	0.91
Long-Term Investments	0.11	0.11	0.10	0.10	0.10	0.10	0.10	0.10
Intangible Assets	1.79	1.90	1.95	2.00	-	-	-	-
Other Noncurrent Operating Assets	1.10	0.53	0.57	0.60	0.68	0.71	0.74	0.81
Total Liabilities & Shareholders' Equity	150	78	58	68	91	57	59	62
Total Liabilities	35	19	12	10	8.23	7.98	5.31	5.76
Total Current Liabilities	34	18	11	9.53	7.67	7.39	4.67	5.06
Accounts Payable	1.93	1.34	3.34	2.83	2.39	2.90	1.45	1.77
Accrued Expenses	32	17	7.61	6.55	5.14	4.34	3.09	3.16
Other Current Liabilities	0.17	0.16	0.16	0.15	0.15	0.14	0.14	0.13
Total Noncurrent Liabilities	0.30	0.39	0.44	0.48	0.56	0.59	0.63	0.70
Other Noncurrent Operating Liabilities	0.30	0.39	0.44	-	-	-	0.63	-
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	115	59	46	58	83	49	54	56
Total Preferred & Common Equity	115	59	46	58	83	49	54	56
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	115	59	46	58	83	49	54	56
Common Stock	434	412	396	394	390	346	340	323
Retained Earnings	-319	-353	-350	-336	-307	-297	-286	-267
Accumulated Other Comprehensive Income / (Loss)	0.08	0.09	0.09	0.08	0.08	0.09	0.10	0.05

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	0.00%	-100.00%	-65.74%
EBITDA Growth	56.11%	-60.58%	-3.74%
EBIT Growth	55.36%	-60.16%	-3.83%
NOPAT Growth	54.34%	-59.87%	-4.03%
Net Income Growth	61.31%	-56.02%	-5.29%
EPS Growth	67.03%	0.00%	0.00%
Operating Cash Flow Growth	-31.78%	-57.70%	-15.13%
Free Cash Flow Firm Growth	-69.72%	-57.81%	-1.79%
Invested Capital Growth	641.51%	-53.29%	-36.42%
Revenue Q/Q Growth	240.63%	-100.00%	-28.98%
EBITDA Q/Q Growth	57.74%	-17.41%	-2.16%
EBIT Q/Q Growth	57.12%	-17.33%	-2.16%
NOPAT Q/Q Growth	56.13%	-17.47%	-2.03%
Net Income Q/Q Growth	61.15%	-16.45%	-1.43%
EPS Q/Q Growth	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	9.20%	-13.57%	-1.19%
Free Cash Flow Firm Q/Q Growth	-6.47%	-13.40%	5.51%
Invested Capital Q/Q Growth	161.29%	-101.22%	-79.85%
Profitability Metrics	-	-	-
Gross Margin	92.66%	0.00%	94.29%
EBITDA Margin	-49.25%	0.00%	-46,443.53%
Operating Margin	-51.43%	0.00%	-46,819.91%
EBIT Margin	-50.30%	0.00%	-46,763.12%
Profit (Net Income) Margin	-41.24%	0.00%	-45,409.90%
Tax Burden Percent	92.78%	100.00%	98.07%
Interest Burden Percent	88.37%	94.60%	99.02%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-116.81%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	-113.25%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	93.64%	0.00%	0.00%
Return on Equity (ROE)	-23.17%	-74.02%	-50.40%
Cash Return on Invested Capital (CROIC)	-166.09%	0.00%	0.00%
Operating Return on Assets (OROA)	-21.77%	0.00%	-46.70%
Return on Assets (ROA)	-17.85%	0.00%	-45.35%
Return on Common Equity (ROCE)	-23.17%	-74.02%	-50.40%
Return on Equity Simple (ROE_SIMPLE)	-21.18%	-66.06%	-53.94%
Net Operating Profit after Tax (NOPAT)	-16	-34	-21
NOPAT Margin	-36.00%	0.00%	-32,773.94%
Net Nonoperating Expense Percent (NNEP)	-3.56%	-17.85%	-13.25%
Return On Investment Capital (ROIC_SIMPLE)	-18.49%	-48.86%	-
Cost of Revenue to Revenue	7.34%	0.00%	5.71%
SG&A Expenses to Revenue	68.92%	0.00%	30,586.61%
R&D to Revenue	9.07%	0.00%	16,327.59%
Operating Expenses to Revenue	144.09%	0.00%	46,914.20%
Earnings before Interest and Taxes (EBIT)	-22	-49	-31
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-21	-49	-30
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	5.63	2.73	3.41
Price to Tangible Book Value (P/TBV)	5.76	2.73	3.41
Price to Revenue (P/Rev)	10.97	0.00	2,871.04
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	12.93	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	9.78	0.00	1,968.73
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	0.00	0.00	0.00
Long-Term Debt to Equity	0.00	0.00	0.00
Financial Leverage	-0.83	-1.08	-1.06
Leverage Ratio	1.30	1.15	1.11
Compound Leverage Factor	1.15	1.09	1.10
Debt to Total Capital	0.00%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%
Debt to EBITDA	0.00	0.00	0.00
Net Debt to EBITDA	0.00	0.00	0.00
Long-Term Debt to EBITDA	0.00	0.00	0.00
Debt to NOPAT	0.00	0.00	0.00
Net Debt to NOPAT	0.00	0.00	0.00
Long-Term Debt to NOPAT	0.00	0.00	0.00
Altman Z-Score	4.94	3.17	9.34
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	3.39	6.97	9.44
Quick Ratio	3.05	6.67	9.32
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-55	-32	-20
Operating Cash Flow to CapEx	-43,735.12%	-11,735.25%	-11,103.54%
Free Cash Flow to Firm to Interest Expense	-1,499.31	-937.74	-768.62
Operating Cash Flow to Interest Expense	-1,390.32	-1,119.94	-918.60
Operating Cash Flow Less CapEx to Interest Expense	-1,393.50	-1,129.48	-926.88
Efficiency Ratios	-	-	-
Asset Turnover	0.43	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00
Inventory Turnover	0.66	0.00	0.00
Fixed Asset Turnover	23.54	0.00	0.04
Accounts Payable Turnover	1.06	0.00	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	555.18	0.00	0.00
Days Payable Outstanding (DPO)	343.19	0.00	215,622.77
Cash Conversion Cycle (CCC)	211.99	0.00	-215,622.77
Capital & Investment Metrics	-	-	-
Invested Capital	33	-6.07	-3.96
Invested Capital Turnover	3.24	0.00	-0.02
Increase / (Decrease) in Invested Capital	39	-2.11	-1.06
Enterprise Value (EV)	425	115	129
Market Capitalization	477	191	188
Book Value per Share	$1.44	$1.28	$1.33
Tangible Book Value per Share	$1.41	$1.28	$1.33
Total Capital	85	70	55
Total Debt	0.00	0.00	0.00
Total Long-Term Debt	0.00	0.00	0.00
Net Debt	-52	-76	-59
Capital Expenditures (CapEx)	0.12	0.33	0.22
Debt-free, Cash-free Net Working Capital (DFCFNWC)	29	-8.06	-5.68
Debt-free Net Working Capital (DFNWC)	81	68	53
Net Working Capital (NWC)	81	68	53
Net Nonoperating Expense (NNE)	2.28	12	8.26
Net Nonoperating Obligations (NNO)	-52	-76	-59
Total Depreciation and Amortization (D&A)	0.46	0.21	0.21
Debt-free, Cash-free Net Working Capital to Revenue	66.82%	0.00%	-8,678.15%
Debt-free Net Working Capital to Revenue	185.72%	0.00%	81,397.21%
Net Working Capital to Revenue	185.72%	0.00%	81,397.21%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($0.30)	($0.91)	($0.74)
Adjusted Weighted Average Basic Shares Outstanding	58.87M	50.90M	40.27M
Adjusted Diluted Earnings per Share	($0.30)	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	58.87M	54.98M	44.50M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	54.98M	44.50M
Normalized Net Operating Profit after Tax (NOPAT)	-16	-34	-21
Normalized NOPAT Margin	-36.00%	0.00%	-32,773.94%
Pre Tax Income Margin	-44.45%	0.00%	-46,305.23%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	-600.66	-1,428.35	-1,153.57
NOPAT to Interest Expense	-429.87	-999.26	-808.48
EBIT Less CapEx to Interest Expense	-603.84	-1,437.90	-1,161.84
NOPAT Less CapEx to Interest Expense	-433.05	-1,008.80	-816.75
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from CorMedix's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	-100.00%	-100.00%	-47.33%	-82.10%
EBITDA Growth	221.84%	187.33%	69.31%	-29.08%	-51.99%	-86.34%	-51.68%	-44.91%	-56.69%	-8.29%	19.23%
EBIT Growth	220.22%	185.94%	68.36%	-29.48%	-51.83%	-85.77%	-51.28%	-44.61%	-56.26%	-8.30%	19.05%
NOPAT Growth	272.11%	217.94%	68.59%	-29.62%	-51.62%	-86.77%	-50.35%	-43.25%	-56.66%	-7.83%	18.72%
Net Income Growth	242.71%	191.26%	71.50%	-25.53%	-36.90%	-79.73%	-42.18%	-48.24%	-50.23%	-5.36%	20.02%
EPS Growth	220.00%	0.00%	70.59%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Growth	214.02%	47.75%	-56.94%	-63.78%	-66.54%	-74.59%	-45.07%	-56.94%	-54.11%	-4.86%	-8.94%
Free Cash Flow Firm Growth	-30.28%	-193.47%	-174.78%	-83.70%	-72.13%	-83.95%	-19.89%	-56.32%	-160.70%	0.95%	9.30%
Invested Capital Growth	15,531.26%	641.51%	517.02%	115.93%	87.29%	-53.29%	-37.01%	-24.23%	2.34%	-36.42%	20.23%
Revenue Q/Q Growth	27.26%	168.07%	777.11%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	335.70%	-67.92%
EBITDA Q/Q Growth	48.78%	525.33%	78.89%	8.78%	-6.64%	-49.49%	11.24%	-7.41%	-30.74%	-21.69%	15.20%
EBIT Q/Q Growth	49.19%	505.46%	78.30%	8.41%	-6.64%	-49.26%	11.18%	-7.39%	-30.49%	-21.55%	15.10%
NOPAT Q/Q Growth	55.58%	662.16%	78.52%	8.40%	-6.61%	-49.69%	11.33%	-7.15%	-31.33%	-20.50%	15.52%
Net Income Q/Q Growth	53.32%	584.89%	80.38%	2.18%	1.95%	-51.41%	13.57%	-6.68%	-28.73%	-19.77%	9.88%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	451.53%	58.87%	2.78%	18.89%	-61.09%	-23.55%	-1.46%	17.52%	-68.87%	-2.66%	-9.76%
Free Cash Flow Firm Q/Q Growth	33.08%	-45.28%	-26.69%	-5.78%	-50.74%	-36.02%	15.30%	0.89%	-61.09%	11.34%	-10.43%
Invested Capital Q/Q Growth	13.44%	161.29%	2,580.55%	294.22%	96.02%	-101.22%	-2.42%	-54.87%	51.97%	-79.85%	7.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	95.91%	97.80%	94.01%	22.68%	0.00%	0.00%	0.00%	0.00%	0.00%	98.63%	78.45%
EBITDA Margin	51.91%	44.40%	-27.98%	-1,162.91%	0.00%	0.00%	0.00%	0.00%	0.00%	-28,211.21%	-101,010.75%
Operating Margin	51.50%	42.12%	-28.70%	-1,171.47%	0.00%	0.00%	0.00%	0.00%	0.00%	-28,244.66%	-102,126.07%
EBIT Margin	51.40%	43.84%	-28.99%	-1,171.59%	0.00%	0.00%	0.00%	0.00%	0.00%	-28,394.28%	-101,780.28%
Profit (Net Income) Margin	52.82%	43.84%	-24.24%	-1,083.48%	0.00%	0.00%	0.00%	0.00%	0.00%	-27,637.70%	-100,538.67%
Tax Burden Percent	100.00%	100.00%	100.00%	100.00%	91.21%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Interest Burden Percent	102.77%	100.00%	83.62%	92.48%	94.93%	94.17%	92.83%	95.39%	96.02%	97.34%	98.78%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	229.55%	136.68%	-53.62%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	228.79%	135.86%	-52.90%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-179.78%	-112.34%	49.34%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	49.77%	24.34%	-4.28%	-111.55%	-89.76%	-74.02%	-57.05%	-66.62%	-58.41%	-50.40%	-46.61%
Cash Return on Invested Capital (CROIC)	-61.83%	-166.09%	-407.60%	-9,401.45%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	39.00%	18.97%	-4.38%	-26.67%	0.00%	0.00%	0.00%	0.00%	0.00%	-28.36%	-136.39%
Return on Assets (ROA)	40.08%	18.97%	-3.66%	-24.66%	0.00%	0.00%	0.00%	0.00%	0.00%	-27.60%	-134.72%
Return on Common Equity (ROCE)	49.77%	24.34%	-4.28%	-111.55%	-89.76%	-74.02%	-57.05%	-66.62%	-58.41%	-50.40%	-46.61%
Return on Equity Simple (ROE_SIMPLE)	14.95%	0.00%	-78.60%	-115.01%	-86.60%	0.00%	-47.83%	-75.23%	-61.63%	0.00%	-52.00%
Net Operating Profit after Tax (NOPAT)	20	13	-2.30	-11	-12	-11	-7.33	-8.26	-7.71	-5.87	-4.87
NOPAT Margin	51.50%	42.12%	-20.09%	-820.03%	0.00%	0.00%	0.00%	0.00%	0.00%	-19,771.26%	-71,488.25%
Net Nonoperating Expense Percent (NNEP)	0.76%	0.83%	-0.72%	-7.04%	-4.86%	-5.60%	-3.34%	-5.19%	-4.85%	-3.75%	-3.03%
Return On Investment Capital (ROIC_SIMPLE)	17.52%	15.28%	-	-	-	-15.64%	-	-	-	-	-
Cost of Revenue to Revenue	4.09%	3.83%	5.99%	39.03%	0.00%	0.00%	0.00%	0.00%	0.00%	1.37%	21.55%
SG&A Expenses to Revenue	24.80%	2.51%	57.44%	578.76%	0.00%	0.00%	0.00%	0.00%	0.00%	18,770.79%	67,889.31%
R&D to Revenue	8.17%	5.62%	6.35%	49.84%	0.00%	0.00%	0.00%	0.00%	0.00%	9,572.50%	34,315.21%
Operating Expenses to Revenue	44.42%	55.68%	122.70%	1,194.16%	0.00%	0.00%	0.00%	0.00%	0.00%	28,343.29%	102,204.52%
Earnings before Interest and Taxes (EBIT)	20	13	-3.32	-15	-17	-16	-10	-12	-11	-8.43	-6.94
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	20	14	-3.21	-15	-17	-16	-10	-12	-11	-8.38	-6.89
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	3.70	5.63	8.10	5.24	4.02	2.73	2.51	4.43	3.48	3.41	2.07
Price to Tangible Book Value (P/TBV)	3.76	5.76	8.37	5.47	4.16	2.73	2.51	4.43	3.48	3.41	2.07
Price to Revenue (P/Rev)	5.15	10.97	37.24	185.19	0.00	0.00	7,044.87	5,950.42	3,251.82	2,871.04	1,268.47
Price to Earnings (P/E)	24.73	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	4.04%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	9.32	12.93	34.12	418.06	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	4.21	9.78	33.63	150.18	0.00	0.00	4,142.11	4,526.62	2,285.45	1,968.73	633.16
Enterprise Value to EBITDA (EV/EBITDA)	22.36	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	23.26	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	23.99	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.00	0.00	0.01
Long-Term Debt to Equity	0.00	0.00	0.00	0.00	0.01	0.00	0.01	0.01	0.00	0.00	0.01
Financial Leverage	-0.79	-0.83	-0.93	-1.03	-1.02	-1.08	-1.04	-1.05	-1.03	-1.06	-1.04
Leverage Ratio	1.26	1.30	1.19	1.21	1.14	1.15	1.10	1.13	1.09	1.11	1.09
Compound Leverage Factor	1.29	1.30	1.00	1.11	1.08	1.08	1.02	1.07	1.05	1.08	1.08
Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.81%	0.00%	0.66%	1.20%	0.00%	0.00%	1.23%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.81%	0.00%	0.66%	1.20%	0.00%	0.00%	1.23%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	100.00%	100.00%	100.00%	100.00%	99.18%	100.00%	99.34%	98.80%	100.00%	100.00%	98.77%
Debt to EBITDA	0.00	0.00	0.00	0.00	-0.01	0.00	-0.01	-0.02	0.00	0.00	-0.02
Net Debt to EBITDA	0.00	0.00	0.00	0.00	1.07	0.00	2.08	1.37	0.00	0.00	1.97
Long-Term Debt to EBITDA	0.00	0.00	0.00	0.00	-0.01	0.00	-0.01	-0.02	0.00	0.00	-0.02
Debt to NOPAT	0.00	0.00	0.00	0.00	-0.01	0.00	-0.02	-0.02	0.00	0.00	-0.03
Net Debt to NOPAT	0.00	0.00	0.00	0.00	1.52	0.00	2.96	1.95	0.00	0.00	2.79
Long-Term Debt to NOPAT	0.00	0.00	0.00	0.00	-0.01	0.00	-0.02	-0.02	0.00	0.00	-0.03
Altman Z-Score	6.24	5.92	9.61	4.10	7.19	4.51	11.25	9.35	14.93	10.51	6.82
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	4.21	3.39	3.96	4.79	6.65	6.97	11.61	7.39	12.15	9.44	11.79
Quick Ratio	3.84	3.05	3.43	4.12	6.14	6.67	11.29	7.09	11.89	9.32	11.66
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-17	-26	-18	-14	-13	-8.86	-6.51	-7.69	-7.76	-4.82	-5.43
Operating Cash Flow to CapEx	193,932.43%	-56,890.63%	-139,769.68%	-40,357.34%	-28,235.89%	-3,631.15%	-84,894.78%	-134,829.03%	-70,390.67%	-4,780.27%	-7,845.58%
Free Cash Flow to Firm to Interest Expense	-1,738.42	-2,597.87	-1,788.21	-2,154.45	-1,357.69	-1,351.17	-496.63	-1,314.10	-883.95	-548.72	-618.93
Operating Cash Flow to Interest Expense	1,972.27	-561.06	-1,364.04	-2,141.54	-1,760.07	-1,639.06	-663.27	-1,465.12	-1,184.35	-701.33	-683.16
Operating Cash Flow Less CapEx to Interest Expense	1,971.25	-562.05	-1,365.01	-2,146.84	-1,766.30	-1,684.20	-664.05	-1,466.21	-1,186.04	-716.00	-691.87
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.76	0.43	0.15	0.02	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.81	0.66	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	2.09
Fixed Asset Turnover	45.44	23.54	7.32	0.74	0.00	0.00	0.02	0.02	0.04	0.04	0.06
Accounts Payable Turnover	1.67	1.06	1.08	0.43	0.38	0.00	0.00	0.00	0.00	0.00	0.04
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	451.02	555.18	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	174.86
Days Payable Outstanding (DPO)	218.86	343.19	337.83	858.02	952.68	0.00	1,867,035.68	525,271.11	263,507.26	215,622.77	10,218.47
Cash Conversion Cycle (CCC)	232.16	211.99	-337.83	-858.02	0.00	0.00	-1,867,035.68	-525,271.11	-263,507.26	-215,622.77	-10,043.60
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	37	33	13	0.47	-0.24	-6.07	-3.02	-2.94	-1.90	-3.96	-2.20
Invested Capital Turnover	4.46	3.24	2.67	-1.06	0.00	0.00	-0.01	-0.01	-0.03	-0.02	-0.04
Increase / (Decrease) in Invested Capital	38	39	16	3.41	1.66	-2.11	-0.81	-0.57	0.05	-1.06	0.56
Enterprise Value (EV)	347	425	429	196	175	115	123	165	132	129	58
Market Capitalization	425	477	475	242	233	191	209	217	188	188	117
Book Value per Share	$1.76	$1.44	$1.00	$0.80	$1.01	$1.28	$1.52	$1.08	$1.21	$1.33	$1.37
Tangible Book Value per Share	$1.73	$1.41	$0.97	$0.77	$0.97	$1.28	$1.52	$1.08	$1.21	$1.33	$1.37
Total Capital	115	85	59	46	58	70	84	50	54	55	57
Total Debt	0.00	0.00	0.00	0.00	0.48	0.00	0.56	0.59	0.00	0.00	0.70
Total Long-Term Debt	0.00	0.00	0.00	0.00	0.48	0.00	0.56	0.59	0.00	0.00	0.70
Net Debt	-78	-52	-46	-46	-58	-76	-86	-52	-56	-59	-59
Capital Expenditures (CapEx)	0.01	0.01	0.01	0.03	0.06	0.30	0.01	0.01	0.01	0.13	0.08
Debt-free, Cash-free Net Working Capital (DFCFNWC)	33	29	8.64	-3.53	-4.75	-8.06	-5.28	-5.25	-3.62	-5.68	-4.51
Debt-free Net Working Capital (DFNWC)	110	81	55	42	54	68	81	47	52	53	55
Net Working Capital (NWC)	110	81	55	42	54	68	81	47	52	53	55
Net Nonoperating Expense (NNE)	-0.52	-0.53	0.48	3.44	2.77	3.79	2.42	3.01	2.86	2.34	1.98
Net Nonoperating Obligations (NNO)	-78	-52	-46	-46	-58	-76	-86	-52	-56	-59	-59
Total Depreciation and Amortization (D&A)	0.20	0.17	0.11	0.11	0.06	0.05	0.05	0.05	0.05	0.05	0.05
Debt-free, Cash-free Net Working Capital to Revenue	39.94%	66.82%	67.73%	-270.06%	0.00%	0.00%	-17,776.99%	-14,377.30%	-6,266.32%	-8,678.15%	-4,898.54%
Debt-free Net Working Capital to Revenue	133.82%	185.72%	428.40%	3,221.99%	0.00%	0.00%	274,026.98%	129,350.11%	90,193.71%	81,397.21%	59,284.64%
Net Working Capital to Revenue	133.82%	185.72%	428.40%	3,221.99%	0.00%	0.00%	274,026.98%	129,350.11%	90,193.71%	81,397.21%	59,284.64%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.32	$0.25	($0.05)	($0.25)	($0.25)	($0.25)	($0.17)	($0.25)	($0.24)	($0.20)	($0.17)
Adjusted Weighted Average Basic Shares Outstanding	65.24M	58.87M	58.83M	57.62M	57.50M	50.90M	56.55M	45.37M	44.09M	40.27M	41.18M
Adjusted Diluted Earnings per Share	$0.30	$0.00	($0.05)	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Diluted Shares Outstanding	68.98M	58.87M	58.83M	55.86M	54.96M	50.90M	54.81M	54.81M	45.38M	44.50M	41.28M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	67.82M	0.00	60.68M	55.86M	54.96M	54.98M	54.81M	54.81M	45.38M	44.50M	41.28M
Normalized Net Operating Profit after Tax (NOPAT)	14	9.06	-2.30	-11	-12	-11	-7.33	-8.26	-7.71	-5.87	-4.87
Normalized NOPAT Margin	36.05%	29.49%	-20.09%	-820.03%	0.00%	0.00%	0.00%	0.00%	0.00%	-19,771.26%	-71,488.25%
Pre Tax Income Margin	52.82%	43.84%	-24.24%	-1,083.48%	0.00%	0.00%	0.00%	0.00%	0.00%	-27,637.70%	-100,538.67%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	2,007.31	1,345.46	-331.83	-2,334.09	-1,698.86	-2,389.80	-800.46	-2,019.82	-1,253.97	-960.99	-790.61
NOPAT to Interest Expense	2,011.12	1,292.70	-229.95	-1,633.71	-1,188.91	-1,672.99	-558.77	-1,412.27	-878.76	-669.15	-555.30
EBIT Less CapEx to Interest Expense	2,006.29	1,344.47	-332.81	-2,339.40	-1,705.09	-2,434.94	-801.25	-2,020.90	-1,255.65	-975.66	-799.31
NOPAT Less CapEx to Interest Expense	2,010.10	1,291.71	-230.93	-1,639.01	-1,195.15	-1,718.13	-559.55	-1,413.36	-880.45	-683.82	-564.01
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Frequently Asked Questions About CorMedix's Financials

When does CorMedix's financial year end?

According to the most recent income statement we have on file, CorMedix's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has CorMedix's net income changed over the last 2 years?

CorMedix's net income appears to be on a downward trend, with a most recent value of -$17.93 million in 2024, falling from -$29.70 million in 2022. The previous period was -$46.34 million in 2023. Find out what analysts predict for CorMedix in the coming months.

What is CorMedix's operating income?

CorMedix's total operating income in 2024 was -$22.36 million, based on the following breakdown:

Total Gross Profit: $40.28 million
Total Operating Expenses: $62.64 million

How has CorMedix revenue changed over the last 2 years?

Over the last 2 years, CorMedix's total revenue changed from $65.41 thousand in 2022 to $43.47 million in 2024, a change of 66,363.1%.

How much debt does CorMedix have?

CorMedix's total liabilities were at $34.19 million at the end of 2024, a 186.9% increase from 2023, and a 389.9% increase since 2022.

How much cash does CorMedix have?

In the past 2 years, CorMedix's cash and equivalents has ranged from $40.65 million in 2024 to $43.64 million in 2023, and is currently $40.65 million as of their latest financial filing in 2024.

How has CorMedix's book value per share changed over the last 2 years?

Over the last 2 years, CorMedix's book value per share changed from 1.33 in 2022 to 1.44 in 2024, a change of 7.8%.

Related Companies

This page (NASDAQ:CRMD) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CorMedix (CRMD) Financials

Frequently Asked Questions About CorMedix's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CorMedix (CRMD) Financials

Annual Income Statements for CorMedix

Quarterly Income Statements for CorMedix

Annual Cash Flow Statements for CorMedix

Quarterly Cash Flow Statements for CorMedix

Annual Balance Sheets for CorMedix

Quarterly Balance Sheets for CorMedix

Annual Metrics And Ratios for CorMedix

Quarterly Metrics And Ratios for CorMedix

Frequently Asked Questions About CorMedix's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools